Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH
NCT04811092Phase 3Terminated
- Start
- Mar 2022
- Primary completion
- Apr 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 27
01
Overview
A Phase 3 trial of sotatercept in pulmonary arterial hypertension (PAH). Started Mar 2022; status: terminated.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04811092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811092.